As the novel coronavirus (Covid-19) seems to be generating multiple strains based on the region and with the migration of the asymptomatic, the world is desperately looking at switching to the stage of developing vaccines. On Monday (21), the World Health Organisation (WHO) in their weekly presser announced that 64 higher income economies had joined the Covid-19 Vaccine Global Access Facility (COVAX Facility) Advance Market Commitment (AMC), which is a global initiative that brings together governments and manufacturers to ensure that eventual Covid-19 vaccines reach those in greatest need, whoever they are and wherever they may live. Sri Lanka has been listed as a lower-middle income country that is eligible to participate in the COVAX Facility supported by the COVAX AMC. These 64 economies include commitments from 35 economies as well as the European Commission, which will procure doses of the vaccine on behalf of 27 EU member states, plus Norway and Iceland. By pooling financial and scientific resources, these participating economies will be able to insure themselves against the failure of any individual vaccine candidate and secure successful vaccines in a cost-effective, targeted way. The 64 members of the facility will be joined by 92 low and middle-income economies eligible for support for the procurement of vaccines through the Gavi COVAX AMC, a financing instrument aimed at supporting the procurement of vaccines for these countries. One-hundred-and-fifty-six economies, representing roughly 64% of the global population in total, are by now either committed to or eligible for the COVAX Facility, with more to follow. COVAX is part of the three pillars of the Access to Covid-19 Tools (ACT) Accelerator that was launched in April 2020 by the WHO, the European Commission, and France in response to the pandemic. It brought together governments, global health organisations, manufacturers, scientists, the private sector, civil society, and philanthropy, with the aim of providing innovative and equitable access to Covid-19 diagnostics, treatments, and vaccines. The WHO stated that it is the only global solution to this pandemic as it ensures people in all corners of the world will get access to Covid-19 vaccines once they are available, regardless of their wealth. Co-ordinated by Gavi, the Vaccine Alliance; the Coalition for Epidemic Preparedness Innovations (CEPI); and the WHO, COVAX will achieve this by acting as a platform that will support the research, development, and manufacturing of a wide range of Covid-19 vaccine candidates, and negotiate their pricing. All participating countries, regardless of the income levels, will have equal access to these vaccines once they are developed. COVAX’s initial aim is to have 2 billion doses available by the end of 2021, which they believe would be enough to protect high-risk and vulnerable people, as well as frontline healthcare workers. For lower-income-funded nations, who would otherwise be unable to afford these vaccines as well as a number of higher-income self-financing countries that have no bilateral deals with manufacturers, COVAX is quite literally a lifeline and the only viable way in which their citizens will get access to Covid-19 vaccines.